Activated protein C induction of MCP-1 in human endothelial cells: a possible role for endothelial cell nitric oxide

W C Hooper1, D J Phillips, M A Renshaw

  • 1Hematologic Diseases Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. chooper@cdc.gov

Thrombosis Research
|October 24, 2001
PubMed

Insights

Activated protein C (APC) upregulates monocyte chemotactic protein-1 (MCP-1) in endothelial cells by inhibiting endothelial cell nitric oxide synthase (eNOS). This suggests a link between coagulation and inflammation via the APC pathway.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Immunology

Background:

  • Activated protein C (APC) traditionally inhibits coagulation factors Va and VIIIa and plasminogen activator inhibitor-1 (PAI-1).
  • Emerging evidence suggests the protein C/protein S pathway links coagulation and inflammation by modulating cytokines and neutrophil activation.

Purpose of the Study:

  • To investigate the effect of APC on monocyte chemotactic protein-1 (MCP-1) and endothelial cell nitric oxide synthase (eNOS) in human umbilical vein endothelial cells (HUVECs).

Main Methods:

  • Ribonuclease protection assay (RPA) to measure RNA levels of MCP-1 and eNOS.
  • Enzyme-linked immunosorbent assay (ELISA) to quantify MCP-1 protein production.
  • Cell viability assays.

Main Results:

  • APC significantly upregulated MCP-1 RNA and protein in HUVECs.
  • APC downregulated eNOS RNA in a concentration-dependent manner without affecting cell viability.
  • Exogenous nitric oxide (NO) inhibited MCP-1 production.

Conclusions:

  • APC may induce MCP-1 production by inhibiting eNOS.
  • These findings support a role for APC in mediating inflammatory responses through the modulation of cytokine production and endothelial cell function.